Browsing by Author "Gatell, JM"
Now showing items 1-2 of 2
-
Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717.
Perez-Molina, JA; Pulido, F; Di Giambenedetto, S; Ribera, E; Moreno, S; Zamora, J; Coscia, C; Alejos, B; Pitch, J; Gatell, JM (2018-11-01)Background: Dual therapy (DT) with a ritonavir-boosted PI (PI/r) plus lamivudine has proven non-inferior (12% margin) to triple therapy (TT) with PI/r plus two nucleos(t)ide reverse transcriptase inhibitors [N(t)RTIs] in ... -
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.
Gonzalez-Cordon, A; Assoumou, L; Camafort, M; Domenech, M; Guaraldi, G; Domingo, P; Rusconi, S; Raffi, F; Katlama, C; Masia, M (2020-11-01)BACKGROUND: Switching from boosted PIs to dolutegravir in virologically suppressed HIV-infected patients with high cardiovascular risk significantly decreased total cholesterol and other proatherogenic lipid fractions at ...